Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use
Mandeep Singh, Thomas L SchwartzSUNY Upstate Medical University, Psychiatry Department, Syracuse, NY, USABackground: Vilazodone is the latest approved antidepressant available in the United States. Its dual mechanism of action combines the inhibition of serotonin transporters while simultaneously pa...
Guardado en:
Autores principales: | Singh M, Schwartz TL |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b60b4fd3c3b345fba41818b2a048eb6a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder
por: Zhang XF, et al.
Publicado: (2015) -
Categorical improvements in disease severity in patients with major depressive disorder treated with vilazodone: post hoc analysis of four randomized, placebo-controlled trials
por: Durgam S, et al.
Publicado: (2016) -
Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
por: Alvarez E, et al.
Publicado: (2014) -
Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults
por: Robert H Howland
Publicado: (2009) -
Daily activity level improvement with antidepressant medications predicts long-term clinical outcomes in outpatients with major depressive disorder
por: Jha MK, et al.
Publicado: (2017)